In addition to the blockade of CTLA-4 and PD-1, other checkpoint molecules such as the T cell immunoglobulin and mucin domain-containing protein 3 (TIM3) and the lymphocyte activation gene 3 (LAG-3) have been used as targets for a monoclonal antibody in GBM clinical trials. Here, CTLA4 is linked to glioblastoma.